BIO-B
BIO-RAD LABORATORIES, INC.
Next earnings Jul 29, 2026 (after close) · consensus $1.77 EPS, $630M rev
Last earnings +0.0% on 2026-04-30
$296.49
▲ 0.00%$296.49▲ +15.03%
over 1Y
L $247.05EODHDH $321.12
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.0%
1W-2.5%
1M-2.5%
3M+6.6%
YTD-5.2%
1Y+15.0%
Hold
Conviction
Horizon
Long (>12mo)
Street · 10 analysts
Buy
Life-science tools franchise with a fortress balance sheet, but flat revenue and a 1.8% operating margin make the low P/E illusory.
Revenue $2.58B · FY2025
The read
Middling fundamentals offset by an attractive price (~257% below fair value) — worth a look on the value angle.
Bio-Rad is a life-science research and clinical-diagnostics instruments company, and its FY2025 financials require careful reading because the headline numbers are distorted by its large marketable-equity holdings. Net income of $760M (up 141.2%) and diluted EPS of $27.85 produce a deceptively cheap 10.9x P/E, but operating income was only $47.2M (down 82.5%, a 1.8% operating margin) on $2.58B of revenue. The gap between $47M of operating profit and $760M of net income is driven by gains on the company's equity holdings — the same mechanism that produced wild swings of +$4.25B (FY2021), -$3.63B (FY2022) and -$1.84B (FY2024). The 'earnings' are therefore largely a mark-to-market artifact, not operating cash generation.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $2.92B | $2.80B | $2.67B | $2.57B | $2.58B |
| Gross profit | $1.64B | $1.57B | $1.43B | $1.38B | $1.34B |
| Operating income | $500M | $483M | $338M | $269M | $47.2M |
| Net income | $4.25B | -$3.63B | -$637M | -$1.84B | $760M |
| Diluted EPS | $140.83 | -$121.79 | -$21.82 | -$65.36 | $27.85 |
| Net margin | 145.6% | -129.5% | -23.9% | -71.9% | 29.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value—
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)0.08
Earnings yield—
FCF yield—
Quality & risk
ROIC (est.)0.4%
Free cash flow$375M
Total debt$1.20B
Net cash-$672M
Piotroski F-Score4/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗144Filing2026-05-28open ↗SDFiling2026-05-13open ↗4Period ending 2026-05-112026-05-13open ↗144Filing2026-05-11open ↗S-8Filing2026-04-30open ↗10-QPeriod ending 2026-03-312026-04-30open ↗8-KPeriod ending 2026-04-302026-04-30open ↗4Period ending 2026-04-242026-04-28open ↗4Period ending 2026-04-242026-04-28open ↗8-KPeriod ending 2026-04-212026-04-24open ↗4Period ending 2026-04-212026-04-23open ↗4Period ending 2026-04-212026-04-23open ↗
Frequently asked
- Is BIO-RAD LABORATORIES, INC. (BIO-B) a buy?
- BIO-B currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. Life-science tools franchise with a fortress balance sheet, but flat revenue and a 1.8% operating margin make the low P/E illusory.
- What is BIO-B's fair value?
- A Modified-Graham model based on BIO-B's SEC fundamentals estimates a fair value of about $1,058.30. It is an estimate from reported earnings, not a price target.
- Is BIO-B overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, BIO-B currently appears undervalued relative to its SEC-grounded earnings power.
- What is BIO-RAD LABORATORIES, INC.'s quality score?
- BIO-B scores 77.60784313725489/100 (grade B+) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0000012208, latest 10-Q filed 2026-04-30) · EODHD · analysis by claude-code · as of 6/21/2026, 8:51:29 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.